NCT05545111 - Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

July 10, 2024

Study Completion Date

July 10, 2024

Conditions

Schizophrenia

Interventions

DRUG

NBI-1117568

Active treatment with orally administered NBI-1117568

DRUG

Placebo

Placebo matching NBI-1117568

Trial Locations (15)

20877

Neurocrine Clinical Site, Gaithersburg

33016

Neurocrine Clinical Site, Miami Lakes

33334

Neurocrine Clinical Site, Oakland Park

44720

Neurocrine Clinical Site, North Canton

63141

Neurocrine Clinical site, St Louis

72211

Neurocrine Clinical Site, Little Rock

72758

Neurocrine Clinical Site, Rogers

75080

Neurocrine Clinical Site, Richardson

75115

Neurocrine Clinical Site, DeSoto

78754

Neurocrine Clinical Site, Austin

90502

Neurocrine Clinical Site, Torrance

90660

Neurocrine Clinical Site, Pico Rivera

91945

Neurocrine Clinical Site, Lemon Grove

92123

Neurocrine Clinical Site, San Diego

08053

Neurocrine Clinical Site, Berlin